DrugPatentWatch Database Preview

Lanreotide acetate - Generic Drug Details

« Back to Dashboard

What are the generic sources for lanreotide acetate and what is the scope of freedom to operate?

Lanreotide acetate is the generic ingredient in one branded drug marketed by Ipsen Pharma and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Lanreotide acetate has seventy-one patent family members in seventeen countries.

There are three drug master file entries for lanreotide acetate. One supplier is listed for this compound.

Summary for lanreotide acetate

International Patents:	71
US Patents:	1
Tradenames:	1
Applicants:	1
NDAs:	1
Drug Master File Entries:	3
Suppliers / Packagers:	1
Bulk Api Vendors:	34
Clinical Trials:	3
Patent Applications:	5,563
DailyMed Link:	lanreotide acetate at DailyMed

Recent Clinical Trials for lanreotide acetate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Ipsen	Phase 1/Phase 2
Ipsen	Phase 3
Ipsen	Phase 4

See all lanreotide acetate clinical trials

Pharmacology for lanreotide acetate

Drug Class	Somatostatin Analog
Mechanism of Action	Somatostatin Receptor Agonists

Synonyms for lanreotide acetate

108736-35-2

118992-92-0

123369-01-7

127984-74-1

127984-74-1 (acetate salt)

3-(2-Naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-L-threoninamide cyclic (2 inverted exclamation marku7)-disulfide acetate

3-(2-Naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-L-threoninamide cyclic (2-->7)-disulfide acetate

3-(2-Naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-L-threoninamide cyclic (2-7)-disulfide

3-(2-Naphthyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-L-threoninamide cyclic (27)-disulfide

3-(2-Naphtyl)-D-Ala-L-Cys(1)-L-Tyr-D-Trp-L-Lys-L-Val-L-Cys(1)-L-Thr-NH2

33928-EP2272827A1

33928-EP2275420A1

33928-EP2295055A2

33928-EP2295416A2

33928-EP2295426A1

33928-EP2295427A1

33928-EP2298748A2

33928-EP2298764A1

33928-EP2298765A1

33928-EP2305642A2

33928-EP2311453A1

33928-EP2311808A1

33928-EP2311829A1

AC1L2FZT

AC1OCEWT

AKOS030573447

AN-33681

Angiopeptin acetate

Autogel

BDBM82470

BIM 23014

Bim-23014

C54H69N11O10S2

CHEBI:135901

CHEMBL1201185

CTK8G7572

DB06791

DC 13-116

GTPL2031

Ipstyl

L-Threoninamide, 3-(1-naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-, cyclic (2-7)-disulfide

L-Threoninamide, 3-(2-naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-, cyclic (2-7)-disulfide

L000343

Lanreotida

Lanreotida [INN-Spanish]

Lanreotide

Lanreotide [INN:BAN]

Lanreotide Autogel

Lanreotide; Angiopeptin; 3-(2-Naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-L-threoninamide cyclic (2-7)-disulfide; 127984-74-1

Lanreotidum

Lanreotidum [INN-Latin]

LS-153748

LS-172394

Nal-cyclo(cys-tyr-trp-lys-val-cys)-thr-NH2

NCGC00181321-01

PUDHBTGHUJUUFI-UHFFFAOYSA-N

SCHEMBL14802383

SCHEMBL34091

Somatulin

Somatulin-Autogel

Somatuline

US Patents and Regulatory Information for lanreotide acetate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ipsen Pharma	SOMATULINE DEPOT	lanreotide acetate	SOLUTION;SUBCUTANEOUS	022074-003	Aug 30, 2007		RX	Yes	Yes
Ipsen Pharma	SOMATULINE DEPOT	lanreotide acetate	SOLUTION;SUBCUTANEOUS	022074-002	Aug 30, 2007		RX	Yes	Yes
Ipsen Pharma	SOMATULINE DEPOT	lanreotide acetate	SOLUTION;SUBCUTANEOUS	022074-003	Aug 30, 2007		RX	Yes	Yes
Ipsen Pharma	SOMATULINE DEPOT	lanreotide acetate	SOLUTION;SUBCUTANEOUS	022074-001	Aug 30, 2007		RX	Yes	Yes			Y
Ipsen Pharma	SOMATULINE DEPOT	lanreotide acetate	SOLUTION;SUBCUTANEOUS	022074-001	Aug 30, 2007		RX	Yes	Yes
Ipsen Pharma	SOMATULINE DEPOT	lanreotide acetate	SOLUTION;SUBCUTANEOUS	022074-003	Aug 30, 2007		RX	Yes	Yes			Y
Ipsen Pharma	SOMATULINE DEPOT	lanreotide acetate	SOLUTION;SUBCUTANEOUS	022074-002	Aug 30, 2007		RX	Yes	Yes			Y

International Patents for lanreotide acetate

Country	Patent Number	Estimated Expiration
South Africa	9601904
Denmark	0778767
Greece	3032947
Australia	713066
Austria	378082
Hong Kong	1067870
World Intellectual Property Organization (WIPO)	9607440

Supplementary Protection Certificates for lanreotide acetate

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0779805	CA 2002 00032	Denmark
0779805	91037	Luxembourg		91037, EXPIRES: 20160511